UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000060319 |
|---|---|
| Receipt number | R000068998 |
| Scientific Title | Examining the effects of a very low dose of caffeine on sprint running performance and reaction time at the start in athletic sprinters |
| Date of disclosure of the study information | 2026/01/10 |
| Last modified on | 2026/01/10 14:07:33 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of very low dose of caffeine on sprint performance
Acronym
A very low dose caffeine and sprinting
Scientific Title
Examining the effects of a very low dose of caffeine on sprint running performance and reaction time at the start in athletic sprinters
Scientific Title:Acronym
A very low dose caffeine and sprinting
Region
| Japan |
Condition
Condition
Not applicable (sprint performance in healthy track-and-field athletes)
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the acute effects of a very low dose of caffeine (1 mg/kg) on sprint running performance and reaction time at the start in athletic sprinters
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
60-m sprint time at 1 h after ingesting caffeine
Key secondary outcomes
60-m sprint velocity and reaction time at the start at 1 h after ingesting caffeine, plasma caffeine concentration before consuming caffeine and immediately after sprint running, and caffeine-induced side effects immediately and 24 h after sprint running
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Capsulated caffeine or placebo (maltitol) at 1 mg/kg is acutely consumed 1 h before sprint running.
Caffeine condition -> at least 48-h wash-out period -> placebo condition
Interventions/Control_2
Capsulated caffeine or placebo (maltitol) at 1 mg/kg is acutely consumed 1 h before sprint running.
Placebo condition -> at least 48-h wash-out period -> caffeine condition
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 25 | years-old | >= |
Gender
Male
Key inclusion criteria
Sprinters, hurdlers, or jumpers engaged in at least 2 hours of daily training for 5 days per week.
Athletes who can complete all-out sprint running.
Key exclusion criteria
An injury making it difficult to perform sprint running;
A mental disorder or cardiovascular disease;
Smoking within the past year;
An allergy to caffeine or the prescribed diet
Target sample size
15
Research contact person
Name of lead principal investigator
| 1st name | Takeshi |
| Middle name | |
| Last name | Hashimoto |
Organization
Ritsumeikan University
Division name
Faculty of Sport and Health Science
Zip code
525-8577
Address
1-1-1, Noji-Higashi, Kusatsu, Shiga
TEL
077-599-4134
thashimo@fc.ritsumei.ac.jp
Public contact
Name of contact person
| 1st name | Takeshi |
| Middle name | |
| Last name | Hashimoto |
Organization
Ritsumeikan University
Division name
Faculty of Sport and Health Science
Zip code
525-8577
Address
1-1-1, Noji-Higashi, Kusatsu, Shiga
TEL
077-599-4134
Homepage URL
thashimo@fc.ritsumei.ac.jp
Sponsor or person
Institute
Ritsumeikan University
Institute
Department
Personal name
Takeshi Hashimoto
Funding Source
Organization
Japanese Ministry of Education, Culture, Sports, Science, and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethics Review Committee for Medical and Health Research Involving Human Subjects (natural Sciences), Ritsumeikan University
Address
1-1-1, Noji-Higashi, Kusatsu, Shiga
Tel
077-599-4175
b-rinri@st.ritsumei.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
立命館大学びわこ・くさつキャンパス（滋賀県）
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 01 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
15
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2023 | Year | 05 | Month | 19 | Day |
Date of IRB
| 2023 | Year | 08 | Month | 23 | Day |
Anticipated trial start date
| 2023 | Year | 08 | Month | 23 | Day |
Last follow-up date
| 2026 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 01 | Month | 10 | Day |
Last modified on
| 2026 | Year | 01 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000068998
